Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Novigenix SA logo — Leader in Immuno-Transcriptomic Precision Medicine solutions

Novigenix SA

Leader in Immuno-Transcriptomic Precision Medicine solutions

Founded 2014 Switzerland Lausanne, Switzerland 26 employees Series B Total: $21.00M AI, Analytics +4

General Information

Company Name Novigenix SA
Founded Year 2014
Location Switzerland Lausanne, Switzerland +2
Founders / Decision Makers
Team member Team member
Employees 26
Industries AI, Analytics, Biotechnology +3
Funding Stage Series B
Social

Get notified when Novigenix SA moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Novigenix SA

NOVIGENIX is a Swiss precision medicine company founded in 2014 that focuses on leveraging ImmunoTranscriptomic technologies to revolutionize disease management, with a primary focus on cancer. Through their proprietary LITOseek platform, which incorporates advanced Machine Learning and artificial intelligence techniques, the company aims to use patient multi-omics data to map the immune system's response to disease onset and progression, ultimately providing personalized insights and solutions to optimize patient therapeutic journeys. This innovation is expected to lead to improved patient outcomes by identifying illnesses, optimizing therapies, and monitoring disease recurrence. Their product roadmap includes immuno-oncology patient stratification tools, early detection and recurrence monitoring for colorectal cancer, and therapy optimization systems for managing cancer patients. In their latest funding round, NOVIGENIX secured a notable $20.00M Series B investment on 15 November 2022. This investment is a testament to the confidence that investors have in the potential of the company's technologies and their ability to make a significant impact in the biotechnology industry. With its headquarters in Switzerland, NOVIGENIX is strategically positioned at the heart of a renowned hub for biotechnology innovation. Their cutting-edge approach and recent investment injection position them well for driving advancements in disease management and patient outcomes.

Taxonomy: Precision Medicine, ImmunoTranscriptomics, AI in Healthcare, Cancer Management, Multi-omics Data Analysis, Therapy Optimization, Immuno-oncology, Disease Recurrence Monitoring, Colorectal Cancer, Patient Stratification, Personalized Medicine, Switzerland, LITOseek Platform

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• - 15 Nov 2022
Grant •••••• 1 •••• •••• 21 Jan 2020

Novigenix SA Alternatives & Competitors

Novigenix SA vs
SENSEERA
SENSEERA Israel

Empowering diagnostics and drug development with AI-driven chromatin liquid biopsy

20 employees
Health Care
Compare Novigenix SA vs SENSEERA
Novigenix SA vs
epiliquid
epiliquid

Making cancer detection accessible for everyone

10 employees
Novigenix SA vs
Owlstone Medical
Owlstone Medical United Kingdom

On a mission to save 100k lives and $1.5B healthcare costs

Undisclosed
208 employees
Health Care, Medical Devices
Compare Novigenix SA vs Owlstone Medical
Also compare with: Novigenix SA vs Pear Bio Pear Bio

FAQ About Novigenix SA

Leader in Immuno-Transcriptomic Precision Medicine solutions
Novigenix SA was founded in 2014.
Novigenix SA is headquartered in Lausanne, Switzerland.
Novigenix SA operates in the following industries: AI, Analytics, Biotechnology, Health Care, Life Sciences, Machine Learning.
Novigenix SA has approximately 26 employees.
Novigenix SA has completed 2 funding rounds, raising a total of $21.00M. The latest funding stage is Series B.
Top alternatives and competitors to Novigenix SA include SENSEERA, epiliquid, Owlstone Medical, Pear Bio, Ophiomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Novigenix SA and SENSEERA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Novigenix SA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy